HuGE Literature Finder
Records
1
-
24
| BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 1 26 (10): 2422-2432. Boyle Eileen M, Ashby Cody, Tytarenko Ruslana G, Deshpande Shayu, Wang Hongwei, Wang Yan, Rosenthal Adam, Sawyer Jeffrey, Tian Erming, Flynt Erin, Hoering Antje, Johnson Sarah K, Rutherford Michael W, Wardell Christopher P, Bauer Michael A, Dumontet Charles, Facon Thierry, Thanendrarajan Sharmilan, Schinke Carolina D, Zangari Maurizio, van Rhee Frits, Barlogie Bart, Cairns David, Jackson Graham, Thakurta Anjan, Davies Faith E, Morgan Gareth J, Walker Brian |
| Dabrafenib and Trametinib in Patients With Tumors With BRAF Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 8 38 (33): 3895-3904. Salama April K S, Li Shuli, Macrae Erin R, Park Jong-In, Mitchell Edith P, Zwiebel James A, Chen Helen X, Gray Robert J, McShane Lisa M, Rubinstein Larry V, Patton David, Williams P Mickey, Hamilton Stanley R, Armstrong Deborah K, Conley Barbara A, Arteaga Carlos L, Harris Lyndsay N, O'Dwyer Peter J, Chen Alice P, Flaherty Keith |
| RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients. Journal of Cancer 2020 4 11 (12): 3543-3550. Li Qian, Huang Helen J, Ma Jing, Wang Yafei, Cao Zeng, Karlin-Neumann George, Janku Filip, Liu Zhiqia |
| Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring BRAF Mutations: A Cohort of the Histology-Independent VE-BASKET Study. JCO precision oncology 2020 9 2 . Raje Noopur, Chau Ian, Hyman David M, Ribrag Vincent, Blay Jean-Yves, Tabernero Josep, Elez Elena, Wolf Jürgen, Yee Andrew J, Kaiser Martin, Landau Heather, Michot Jean-Marie, Hollebecque Antoine, Veronese Luisa, Makrutzki Martina, Pitcher Bethany, Puzanov Igor, Baselga Jo |
| EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. Clinical lymphoma, myeloma & leukemia 2019 Aug . Goldsmith Scott R, Fiala Mark A, O'Neal Julie, Souroullas George P, Toama Wael, Vij Ravi, Schroeder Mark |
| Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia 2019 Jan . Nagao Yuhei, Mimura Naoya, Takeda June, Yoshida Kenichi, Shiozawa Yusuke, Oshima Motohiko, Aoyama Kazumasa, Saraya Atsunori, Koide Shuhei, Rizq Ola, Hasegawa Yoshinori, Shiraishi Yuichi, Chiba Kenichi, Tanaka Hiroko, Nishijima Dai, Isshiki Yusuke, Kayamori Kensuke, Kawajiri-Manako Chika, Oshima-Hasegawa Nagisa, Tsukamoto Shokichi, Mitsukawa Shio, Takeda Yusuke, Ohwada Chikako, Takeuchi Masahiro, Iseki Tohru, Misawa Sonoko, Miyano Satoru, Ohara Osamu, Yokote Koutaro, Sakaida Emiko, Kuwabara Satoshi, Sanada Masashi, Iwama Atsushi, Ogawa Seishi, Nakaseko Chia |
| KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma. Frontiers in oncology 2019 9 1137. Pasca Sergiu, Tomuleasa Ciprian, Teodorescu Patric, Ghiaur Gabriel, Dima Delia, Moisoiu Vlad, Berce Cristian, Stefan Cristina, Ciechanover Aaron, Einsele Herm |
| Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma. Scientific reports 2018 Sep 8 (1): 13522. Wong Kwan Yeung, Yao Qiumei, Yuan Ling-Qing, Li Zhenhai, Ma Edmond Shiu Kwan, Chim Chor Sa |
| Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients. Clinical lymphoma, myeloma & leukemia 2018 May . Cheung Coty H Y, Cheng Chi Keung, Lau Kin-Mang, Ip Rosalina K L, Chan Nelson C N, Tam Tommy H C, Wong Raymond S M, Raghupathy Radha, Chan Natalie P H, Ng Margaret H |
| Risk Stratification and Targets in Multiple Myeloma: From Genomics to the Bedside. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2018 May (38): 675-680. Perrot Aurore, Corre Jill, Avet-Loiseau Her |
| A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood cancer journal 2018 3 8 (3): 35. White Brian S, Lanc Irena, O'Neal Julie, Gupta Harshath, Fulton Robert S, Schmidt Heather, Fronick Catrina, Belter Edward A, Fiala Mark, King Justin, Ahmann Greg J, DeRome Mary, Mardis Elaine R, Vij Ravi, DiPersio John F, Levy Joan, Auclair Daniel, Tomasson Michael |
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 2018 6 132 (6): 587-597. Walker Brian A, Mavrommatis Konstantinos, Wardell Christopher P, Ashby T Cody, Bauer Michael, Davies Faith E, Rosenthal Adam, Wang Hongwei, Qu Pingping, Hoering Antje, Samur Mehmet, Towfic Fadi, Ortiz Maria, Flynt Erin, Yu Zhinuan, Yang Zhihong, Rozelle Dan, Obenauer John, Trotter Matthew, Auclair Daniel, Keats Jonathan, Bolli Niccolo, Fulciniti Mariateresa, Szalat Raphael, Moreau Philippe, Durie Brian, Stewart A Keith, Goldschmidt Hartmut, Raab Marc S, Einsele Hermann, Sonneveld Pieter, San Miguel Jesus, Lonial Sagar, Jackson Graham H, Anderson Kenneth C, Avet-Loiseau Herve, Munshi Nikhil, Thakurta Anjan, Morgan Gareth |
| Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nature communications 2017 May 8 15086. Kis Olena, Kaedbey Rayan, Chow Signy, Danesh Arnavaz, Dowar Mark, Li Tiantian, Li Zhihua, Liu Jessica, Mansour Mark, Masih-Khan Esther, Zhang Tong, Bratman Scott V, Oza Amit M, Kamel-Reid Suzanne, Trudel Suzanne, Pugh Trevor |
| Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation. Oncogenesis 2017 May 6 (5): e337. Xu J, Pfarr N, Endris V, Mai E K, Md Hanafiah N H, Lehners N, Penzel R, Weichert W, Ho A D, Schirmacher P, Goldschmidt H, Andrulis M, Raab M |
| Genomics of Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Mar 35 (9): 963-967. Robiou du Pont Sebastien, Cleynen Alice, Fontan Charlotte, Attal Michel, Munshi Nikhil, Corre Jill, Avet-Loiseau Her |
| Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood cancer journal 2017 Feb 7 (2): e537. Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder |
| The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 2017 Feb . Stein Caleb K, Pawlyn Charlotte, Chavan Shweta, Rasche Leo, Weinhold Niels, Corken Adam, Buros Amy, Sonneveld Pieter, Jackson Graham H, Landgren Ola, Mughal Tariq, He Jie, Barlogie Bart, Leif Bergsagel P, Davies Faith E, Walker Brian A, Morgan Gareth |
| Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation. Oncotarget 2015 Sep 6 (27): 24205-17. Lionetti Marta, Barbieri Marzia, Todoerti Katia, Agnelli Luca, Marzorati Simona, Fabris Sonia, Ciceri Gabriella, Galletti Serena, Milesi Giulia, Manzoni Martina, Mazzoni Mara, Greco Angela, Tonon Giovanni, Musto Pellegrino, Baldini Luca, Neri Antoni |
| [Cytogenetic abnormalities in high-risk multiple myeloma]. Nihon rinsho. Japanese journal of clinical medicine 2015 Jan 73 (1): 28-32. Ishida Tad |
| BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis. Blood cancer journal 2015 5 e299. Rustad E H, Dai H Y, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda L A, Sandvik A K, Wader K F, Misund K, Sundan A, Aarset H, Waage |
| Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer cell 2014 Jan 25 (1): 91-101. Lohr Jens G, Stojanov Petar, Carter Scott L, Cruz-Gordillo Peter, Lawrence Michael S, Auclair Daniel, Sougnez Carrie, Knoechel Birgit, Gould Joshua, Saksena Gordon, Cibulskis Kristian, McKenna Aaron, Chapman Michael A, Straussman Ravid, Levy Joan, Perkins Louise M, Keats Jonathan J, Schumacher Steven E, Rosenberg Mara, , Getz Gad, Golub Todd |
| Targeting the BRAF V600E mutation in multiple myeloma. Cancer discovery 2013 Aug 3 (8): 862-9. Andrulis Mindaugas, Lehners Nicola, Capper David, Penzel Roland, Heining Christoph, Huellein Jennifer, Zenz Thorsten, von Deimling Andreas, Schirmacher Peter, Ho Anthony D, Goldschmidt Hartmut, Neben Kai, Raab Marc |
| Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias. American journal of blood research 2013 3 (2): 181-5. Hatzimichael Eleftheria, Murray Samuel, Briasoulis Evangel |
| Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. American journal of hematology 2012 Sep . Mosca L, Musto P, Todoerti K, Barbieri M, Agnelli L, Fabris S, Tuana G, Lionetti M, Bonaparte E, Sirchia SM, Grieco V, Bianchino G, D'Auria F, Statuto T, Mazzoccoli C, De Luca L, Petrucci MT, Morabito F, Offidani M, Di Raimondo F, Falcone A, Caravita T, Omedè P, Boccadoro M, Palumbo A, Neri A |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: